tiprankstipranks
Trending News
More News >
Ellen AB (SE:LNFI)
:LNFI
Sweden Market

Ellen AB (LNFI) AI Stock Analysis

Compare
0 Followers

Top Page

SE:LNFI

Ellen AB

(LNFI)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 5.2)
Rating:49Neutral
Price Target:
kr0.81
▼(-3.45% Downside)
The score is driven primarily by mixed financial performance: cash flow turned positive and losses narrowed, but revenue fell and profitability remains negative with equity erosion. Technicals are weak with the price below key longer-term moving averages and a negative MACD. Valuation is constrained by a negative P/E and no dividend support.

Ellen AB (LNFI) vs. iShares MSCI Sweden ETF (EWD)

Ellen AB Business Overview & Revenue Model

Company DescriptionEllen AB (publ), a biotech company, develops and sells self-care products for women's intimate health. It offers ellen Probiotic Tampon products that supply probiotic lactic acid bacteria to the vagina while simultaneously offering sanitary protection; and ellen Probiotic Intimate Crème, a moisturizing intimate cream that acts as a protective barrier for skin and mucous membranes. The company also provides ellen pH-Control, a medical device, which is used to measure the vaginal pH at home; and ellen Sport Tampong/Aqua Block, which is designed to prevent chlorinated or contaminated water from seeping into the vagina while swimming or in other water activities. In addition, it offers LN Intimate Cleansing Foam to clean intimate areas, as well as used as a shaving cream for intimate grooming; LN Intimate Deo, a softening intimate deodorant formulated with lactic acid to promote a healthy vaginal flora and vaginal pH; and LN After Shave & Wax Gel that soothes the skin after shaving or waxing intimate areas or other parts of body. It operates in France, Belgium, Germany, Switzerland, Austria, Scandinavia, and other countries. The company sells its products through distributors and retailers; and through online in Scandinavia. Ellen AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
How the Company Makes Money

Ellen AB Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Ellen AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
kr9.53M-5.01
42
Neutral
kr1.97M-0.05
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:LNFI
Ellen AB
0.89
-0.13
-12.75%
DE:S21
S2Medical AB Class B
DE:9F1
Diagonal Bio AB
0.10
0.00
0.00%
DE:651
LifeClean International AB
0.01
-0.08
-88.89%
DE:N170
Clemondo Group AB
0.83
0.26
45.61%
SE:CMH
Chordate Medical Holding AB
0.80
-9.82
-92.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 04, 2026